UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2005.
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT FOR THE
TRANSITION PERIOD FROM _______________ to______________
Commission file number: 0-16159
LECTEC CORPORATION
----------------------------------------------------------------
(Exact name of small business issuer as specified in its charter)
Minnesota 41-1301878
- --------------------------------------- --------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
5616 Lincoln Drive, Edina, Minnesota 55436
- ------------------------------------------ --------------------
(Address of principal executive offices) (Zip Code)
(952) 933-2291
--------------------------
(Issuer's telephone number)
Not Applicable
--------------------------
(Former name, former address and former fiscal year, if changed from
last report)
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days:
Yes [X] No [ ]
Indicate by check mark whether registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
Yes [ ] No [X]
The number of shares outstanding of the issuer's common stock as of November 14,
2005 was 4,148,998 shares.
Transitional Small Business Disclosure Format (Check one):
Yes [ ] No [X]
LECTEC CORPORATION
REPORT ON FORM 10-QSB FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2005
TABLE OF CONTENTS
PART I - FINANCIAL INFORMATION
Item 1. Condensed Financial Statements and Notes to Condensed
Financial Statements........................................... I-1
Item 2. Management's Discussion and Analysis or Plan of Operation...... I-9
Item 3. Controls and Procedures ....................................... I-12
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.............................................. II-1
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.... II-1
Item 3. Defaults Upon Senior Securities................................ II-1
Item 4. Submission of Matters to a Vote of Security Holders ........... II-1
Item 5. Other Information.............................................. II-1
Item 6. Exhibits....................................................... II-1
Signature Page................................................. II-2
FORWARD-LOOKING STATEMENTS
From time to time, in reports filed with the Securities and Exchange
Commission (including this Form 10-QSB), in press releases, and in other
communications to shareholders or the investment community, the Company may
provide forward-looking statements concerning possible or anticipated future
results of operations or business developments which are typically preceded by
the words "believes", "expects", "anticipates", "intends", "will", "may",
"should" or similar expressions. Such forward-looking statements are subject to
risks and uncertainties which could cause results or developments to differ
materially from those indicated in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the Company's dependence on
royalty payments from Novartis Consumer Health, Inc. ("Novartis") and on key
personnel, the success or failure of any attempt by the Company to protect or
enforce its patents, issuance of new accounting pronouncements; available
opportunities for licensing agreements related to patents that the Company
holds, and other risks and uncertainties as described in the "Cautionary
Statements" filed as Exhibit 99.01 to the Company's Report on Form 10-KSB for
the year ended December 31, 2004.
PART 1 - FINANCIAL INFORMATION
ITEM 1 - CONDENSED FINANCIAL STATEMENTS AND NOTES TO CONDENSED FINANCIAL
STATEMENTS
LECTEC CORPORATION
CONDENSED BALANCE SHEETS
September 30, December 31,
ASSETS 2005 2004
-------------- ------------
(Unaudited)
CURRENT ASSETS:
Cash and cash equivalents $ 1,354,788 $ 2,239,318
Royalty receivable 69,611 -
Prepaid expenses and other 75,188 137,981
Discontinued operations - 192,629
-------------- ------------
Total current assets 1,499,587 2,569,928
-------------- ------------
OTHER ASSETS:
Patents and trademarks 97,587 50,693
Prepaid insurance - director and officer 152,094 182,513
-------------- ------------
249,681 233,206
-------------- ------------
$ 1,749,268 $ 2,803,134
============== ============
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Current maturities of long-term obligations $ - $ 2,525
Accounts payable 52,975 4,944
Accrued expenses 73,553 240,293
Discontinued operations 98,350 273,290
-------------- ------------
Total current liabilities 224,878 521,052
-------------- ------------
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Common stock, $.01 par value; 15,000,000 shares
authorized; 4,148,998 and
4,030,330 shares issued and outstanding at
September 30, 2005 and December 31, 2004, respectively 41,490 40,303
Additional contributed capital 11,847,536 11,689,404
Accumulated deficit (10,364,636) (9,447,625)
-------------- ------------
1,524,390 2,282,082
-------------- ------------
$ 1,749,268 $ 2,803,134
============== ============
Note: The balance sheet as of December 31, 2004 has been condensed from the
audited financial statements.
The accompanying notes are an integral part of these condensed financial
statements.
I-1
LECTEC CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2005 2004 2005 2004
------------- ------------- ------------- --------------
(Restated) (Restated)
CONTINUING OPERATIONS:
Revenue - royalty and licensing fee income $ 68,717 $ 1,065,000 $ 189,195 $ 1,065,000
Operating expenses 87,850 315,492 653,292 907,866
------------- ------------- ------------- --------------
Earnings (loss) from continuing operations
before income taxes (19,133) 749,508 (464,097) 157,134
Income tax expense - 1,825 - 1,825
------------- ------------- ------------- --------------
Earning (loss) from continuing operations $ (19,133) $ 747,683 $ (464,097) $ 155,309
------------- ------------- ------------- --------------
DISCONTINUED OPERATIONS:
Earnings (loss) from discontinued operations
before income taxes $ 19,512 $ 421,913 $ (206,090) $ 1,097,853
Income tax expense - 12,757 - 12,757
------------- ------------- ------------- --------------
Earning (loss) from discontinued operations $ 19,512 $ 409,156 $ (206,090) $ 1,085,096
------------- ------------- ------------- --------------
NET EARNINGS (LOSS) $ 379 $ 1,156,839 $ (670,187) $ 1,240,405
============= ============= ============= ==============
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic 4,148,998 4,021,899 4,129,262 4,005,831
============= ============= ============= ==============
Diluted 4,148,998 4,174,772 4,129,262 4,121,212
============= ============= ============= ==============
EARNINGS (LOSS) PER SHARE:
Basic:
Continuing operations $ (0.00) $ 0.19 $ (0.11) $ 0.04
Discontinued operations 0.00 0.10 (0.05) 0.27
------------- ------------- ------------- --------------
Total $ 0.00 $ 0.29 $ (0.16) $ 0.31
============= ============= ============= ==============
Diluted:
Continuing operations $ (0.00) $ 0.18 $ (0.11) $ 0.04
Discontinued operations 0.00 0.10 (0.05) 0.26
------------- ------------- ------------- --------------
Total $ 0.00 $ 0.28 $ (0.16) $ 0.30
============= ============= ============= ==============
The accompanying notes are an integral part of these condensed financial
statements.
I-2
LECTEC CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine Months ended
September 30,
2005 2004
----------- -----------
(Restated)
Cash flows from operating activities:
Earnings (loss) from continuing operations $ (464,097) $ 155,309
Adjustments to reconcile net earnings (loss) to net cash provided by
(used in) operating activities:
Earnings (loss) from discontinued operations (206,090) 1,085,096
Loss on impaired assets - 115,054
Depreciation and amortization 13,106 205,740
Gain on sale of property, plant and equipment - (138,055)
Compensation expense related to re-priced stock options 69,092 95,040
Changes in continuing operations assets and liabilities:
Royalty receivable (69,611) -
Prepaid expenses and other 93,212 (129,048)
Accounts payable 48,031 (2,136)
Accrued expenses (166,740) 53,044
Change in net assets and liabilities of discontinued operations 17,689 113,917
----------- -----------
Net cash provided by (used in) operating activities (665,408) 1,553,961
----------- -----------
Cash flows from investing activities:
Investment in patents (60,000) (31,473)
Purchases of property, plant and equipment - (74,550)
Proceeds from sales of property, plant and equipment - 162,700
----------- -----------
Net cash provided by (used in) investing activities (60,000) 56,677
----------- -----------
Cash flows from financing activities:
Cash dividends paid (246,824) -
Proceeds from exercise of stock options 90,227 24,911
Repayment of long-term obligations (2,525) (9,177)
----------- -----------
Net cash provided by (used in) financing activities (159,122) 15,734
----------- -----------
Net increase (decrease) in cash and cash equivalents (884,530) 1,626,372
Cash and cash equivalents - beginning of period 2,239,318 483,844
----------- -----------
Cash and cash equivalents - end of period $ 1,354,788 $ 2,110,216
=========== ===========
Supplemental disclosures of cash flow information:
Cash paid for interest $ 4,126 $ 6,804
Licensing fees used to reduce long-term obligations and accrued interest - 250,000
The accompanying notes are an integral part of these condensed financial
statements.
I-3
LECTEC CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
(UNAUDITED)
(1) GENERAL
The accompanying condensed financial statements include the accounts of
LecTec Corporation (the "Company") as of September 30, 2005 and December 31,
2004 and for the three and nine month periods ended September 30, 2005 and 2004.
The Company's condensed financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America
and should be read in conjunction with the Company's Annual Report on Form
10-KSB for the year ended December 31, 2004. The interim condensed financial
statements are unaudited and in the opinion of management, reflect all
adjustments necessary for a fair presentation of results for the periods
presented. Results for interim periods are not necessarily indicative of results
for the full year.
(2) BUSINESS SUMMARY AND CRITICAL ACCOUNTING POLICIES
BUSINESS SUMMARY
The Company is an intellectual property licensing and holding company.
The Company receives royalties and licensing fees from licensing agreements
pertaining to the Company's patents. The Company has one licensing agreement
("Novartis Agreement" or "Agreement") with Novartis Consumer Health, Inc.
("Novartis"), which pays royalties to the Company on a semi-annual basis or from
time to time based upon a percentage of Novartis net sales of licensed products.
The Company was a contract manufacturer of hydrogel topical patches which were
sold to major pharmaceutical customers until the Company ceased its
manufacturing operations in December 2004. See the discussion under "Licensing
and Supply Agreement" in Note 5 of Notes to Condensed Financial Statements for a
description of the agreement with Novartis.
CRITICAL ACCOUNTING POLICIES
The Company's critical accounting policies include:
Revenue Recognition. Royalty and licensing income is recognized when
earned under the terms of the agreements with customers and collection is
reasonably assured. Revenue from sales from discontinued operations were
recognized when the product was shipped to the customer and collection was
probable.
Long-Lived Assets. The carrying value of long-lived assets is
reviewed periodically or when factors indicating impairment are present. The
amount of impairment loss is measured as the amount by which the carrying
value of the assets exceeds the fair value of the assets. The Company believes
no impairment exists as of September 30, 2005. Patent costs are amortized over
five years.
Royalty Receivable. The Company has a royalty receivable under the
terms of an Agreement with Novartis. The Company granted credit to Novartis in
the normal course of business and management believes, based upon past
experience, that all amounts outstanding are fully collectible. Royalty income
recognized during the three and nine months ended September 30, 2005 is based on
net sales information provided by Novartis, covering sales of products under
the licensing agreement for the applicable periods. Pursuant to the Agreement,
the Company has the right to audit the validity of the net annual sales of
products covered under the Agreement. See the discussion under "Licensing and
Supply Agreement" in Note 5 of Notes to Condensed Financial Statements for a
description of the Agreement with Novartis.
I-4
Accounting for Discontinued Operations. Under the provisions of Statement
of Financial Accounting Standard ("SFAS") No. 144, if a component of an entity
is either classified as held-for-sale or has been disposed of during the period,
the results of its operations are to be reported in discontinued operations,
provided that both of the following conditions are met:
- The operations and cash flows of the component have been or
will be removed from the ongoing operations of the entity as a
result of the disposal transaction, and
- The entity will have no significant continuing involvement in
the operations of the component after the disposal
transaction.
The Company exited from manufacturing operations of topical patches and
sold off substantially all of its manufacturing assets related to the production
of patches to its only remaining customer, Novartis, as of December 31, 2004.
The assets related to the Company's manufacturing operations have been
classified as discontinued operations due to the sale of the manufacturing
assets prior to December 31, 2004. The operations and cash flows of the contract
manufacturing operations were eliminated from the ongoing operations as a result
of the sale transaction. The surviving entity (intellectual property licensing
and holding company) will not have any significant involvement in the operations
of the previously sold manufacturing operations. It is therefore management's
position that the conditions for reporting the Company's financial statements
under the requirements of SFAS 144 as discontinued operations have been
satisfied. The comparative 2004 condensed statements of operations and cash
flows have been restated to conform to the 2005 presentation.
The Company used reasonable judgment combined with quantitative analysis
in determining the amounts of assets, liabilities, revenues and expenses that
would be allocated between continuing operations and discontinued operations.
Stock Based Compensation. In January 2005, the Company extended the
exercise period for options held by two former executive officers of the Company
and one former employee by two years from the date of their respective
termination dates (but not longer than the stock options normal expiration date,
if earlier). There were 222,667 options with a weighted average exercise price
of $0.83 per share subject to the modification in the exercise period. Normally,
these options would expire ninety days from the employees termination date.
Because of the modification to the terms related to the exercise period granted
to those former employees, the Company recorded a one time compensation expense
of $99,957 during the first quarter ended March 31, 2005.
In July 2002, 803,958 stock options with a weighted average exercise price
of $4.54 per share were re-priced to $0.81 per share. At September 30, 2005,
95,000 of these options were outstanding and exercisable. No compensation
expense was recorded by the Company in connection with the re-pricing because
the exercise price exceeded the market price on the date of the re-pricing. On
September 30, 2005, the market price for the Company's common stock was $0.75,
and below the exercise price of the re-priced options. Accordingly, the Company
incrementally reversed previously recorded compensation expense of $75,900 for
the three months ended September 30, 2005, effectively adjusting the
compensation expense back to the re-priced value of $081 per share. For the nine
months ended September 30, 2005, the Company recorded net compensation expense
of $69,092 in connection with the re-pricing and modified options.
The Company utilizes the intrinsic value method of accounting for stock
based employee compensation plans. All options granted had an exercise price
equal to the market value of the underlying common stock on the date of grant,
and no compensation cost related to stock option grants is reflected in net
income or loss for the three and nine months ended September 30, 2005 and 2004.
The following table illustrates the effect on net earnings (loss) if the Company
had applied the fair value recognition provisions of SFAS No. 123, Accounting
for Stock-Based Compensation:
I-5
Three months ended Nine months ended
September 30, September 30,
-------------------------------- --------------------------------
2005 2004 2005 2004
------------- ------------- ------------- -------------
Net earnings (loss), as reported $ 379 $ 1,156,839 $ (670,187) $ 1,240,405
Compensation income (expense)
determined under the fair value
method 116 (26,768) 352 (80,344)
------------- ------------- ------------- -------------
Proforma net earnings (loss) $ 495 $ 1,130,071 $ (669,835) $ 1,160,061
============= ============= ============= =============
Net earnings (loss) per share:
As reported -
Basic earnings (loss) per share:
Continuing operations $ (0.00) $ 0.19 $ (0.11) $ 0.04
Discontinued operations 0.00 0.10 (0.05) 0.27
------------- ------------- ------------- -------------
Total $ 0.00 $ 0.29 $ (0.16) $ 0.31
============= ============= ============= =============
Diluted earnings (loss) per share:
Continuing operations $ (0.00) $ 0.18 $ (0.11) $ 0.04
Discontinued operations 0.00 0.10 (0.05) 0.26
------------- ------------- ------------- -------------
Total $ 0.00 $ 0.28 $ (0.16) $ 0.30
============= ============= ============= =============
Proforma -
Basic earnings (loss) per share:
Continuing operations $ (0.00) $ 0.18 $ (0.11) $ 0.02
Discontinued operations 0.00 0.10 (0.05) 0.27
------------- ------------- ------------- -------------
Total $ 0.00 $ 0.28 $ (0.16) $ 0.29
============= ============= ============= =============
Diluted earnings (loss) per share:
Continuing operations $ (0.00) $ 0.17 $ (0.11) $ 0.02
Discontinued operations 0.00 0.10 (0.05) 0.26
------------- ------------- ------------- -------------
Total $ 0.00 $ 0.27 $ (0.16) $ 0.28
============= ============= ============= =============
The proforma information above should be read in conjunction with the
related historical information.
There were no stock options granted during the nine months ended September
30, 2005. The weighted average fair value of options granted during the nine
months ended September 30, 2004 was $1.09. The fair value of each option grant
is estimated on the date of grant using the Black-Scholes option valuation model
with the following weighted-average assumptions used for all grants during the
nine months ended September 30, 2004 and 2005; zero dividend yield, expected
volatility of 179%, risk-free interest rate of 2.72% and expected life of 3.0
years.
Management believes the Black-Scholes option valuation model currently
provides the best estimate of fair value. However, the Black-Scholes option
valuation model was developed for use in estimating the fair value of traded
options, which have no vesting restrictions and are fully transferable. In
addition, option valuation models require the input of several subjective
assumptions. The Company's employee and director stock options have
characteristics different from those of traded options, and changes in the
subjective input assumptions can materially affect the fair value estimate.
(3) EARNINGS (LOSS) PER SHARE
Basic earnings (loss) per share is computed by dividing net earnings
(loss) by the weighted average number of common shares outstanding. Diluted
earnings (loss) per share is computed by dividing net earnings (loss) by the
weighted average number of common shares outstanding and common share
equivalents related to stock options and warrants when dilutive.
I-6
Common stock options and warrants to purchase 250,200 and 601,417 shares
of common stock with a weighted average exercise price of $3.48 and $1.98 were
outstanding during the three and nine months ended September 30, 2005,
respectively. Common stock options and warrants to purchase 266,028 and 373,472
shares of common stock with a weighted average exercise price of $4.55 and $3.62
were outstanding during the three and nine months ended September 30, 2004,
respectively. These shares were excluded from the earnings (loss) per share
computations because they were antidilutive.
(4) INCOME TAXES
The provision for income taxes for the three and nine months ended
September 30, 2005, was offset principally by a valuation allowance for deferred
taxes. Federal and state income taxes of $14,582 were provided for the three and
nine months ended September 30, 2004, due to having alternative minimum taxable
income after using available tax credits and net operating loss carryforwards.
(5) LICENSING AND SUPPLY AGREEMENT
On July 19, 2004, the Company entered into the Novartis Agreement,
effective as of January 1, 2004. The Agreement replaced the Company's prior
licensing and supply agreement with Novartis dated May 8, 2002. The Agreement
required the Company to manufacture, sell and deliver to Novartis vapor patches
for sale to the pediatric market in the United States, Canada and Mexico. In
order to provide the Company with working capital funds necessary to enable it
to manufacture and deliver vapor patches to Novartis in accordance with the
Agreement, Novartis advanced up to $2,000,000 for use by the Company to pay
accounts payable and expenses incurred exclusively for the manufacture and
delivery of vapor patches. In consideration of any advanced funds, the Company
executed and delivered to Novartis a promissory note of $2,000,000 and a
security agreement. Under the security agreement, the Company pledged
substantially all of its assets. The Company repaid the note by the delivery to
Novartis of vapor patches under the Agreement. All amounts owed were repaid as
of December 31, 2004. Under the Agreement, Novartis had the option until March
31, 2005, to extend the use of vapor patches to the adult cough/cold category in
the United States, Canada and Mexico at no additional cost and under the same
terms and conditions as set forth in the Agreement. On March 31, 2005, Novartis
notified the Company of its desire to exercise the option to enter the adult
market pursuant to the Agreement. There can be assurance that Novartis will
actually introduce any product into the adult market.
Under the Agreement, the Company granted Novartis an exclusive license
(the "License") to all of the intellectual property of the Company to the extent
that it is used or useful in the production of the vapor patches being supplied
under the Agreement for a fee of $1,065,000, which was paid to the Company by
Novartis as follows: (1) release of $250,000 in promissory note debt as of the
date of the Agreement, (2) payment of $407,500 in cash in July 2004, and (3)
payment of $407,500 in cash in September 2004. The License began on July 19,
2004, and will continue for the duration of any patents included in the licensed
intellectual property and, with respect to all other elements of the licensed
intellectual property, for the maximum duration permitted under applicable law
(fourteen years). Upon the expiration of the patents included in the licensed
intellectual property, Novartis will have a non-revocable, perpetual, fully
paid-up license to the intellectual property used or useful in the production of
vapor patches for the pediatric market and the adult cough/cold market.
Commencing on January 1, 2005, Novartis is required by the Agreement to pay
royalties, at an agreed upon percentage, to the Company, based upon the net
sales of vapor patches by Novartis for each year the License is in effect.
The supply portion of the Agreement concluded on February 5, 2005,
however, the provisions relating to the License will continue in effect until
the conclusion of the term of the License. The Company may not assign or
otherwise transfer the Agreement (other than to an affiliate) without the prior
written consent of Novartis. Novartis may object to an assignment only if such
acquirer or successor is a direct competitor of Novartis.
In conjunction with the signing of the Agreement, Novartis purchased
certain manufacturing equipment from the Company for approximately $900,000
during the second half of 2004.
As of September 30, 2005, the Company has received royalty payments of
$119,584 based on net sales by Novartis of products covered under the Agreement
that were sold during the first six months ended June 30, 2005.
I-7
(6) DISCONTINUED OPERATIONS
Discontinued operations assets and liabilities and income statement information
include the following:
September 30, December 31,
2005 2004
------------- ------------
DISCONTINUED OPERATIONS - ASSETS
Accounts receivable, net $ - $ 176,207
Prepaid expenses and other - 16,422
------------- ------------
Total discontinued operations - assets $ - $ 192,629
============= ============
DISCONTINUED OPERATIONS - LIABILITIES
Accounts payable $ - $ 21,267
Accrued expenses - 152,023
Reserve for sales returns and credits 98,350 100,000
------------- ------------
Total discontinued operations - liabilities $ 98,350 $ 273,290
============= ============
DISCONTINUED OPERATIONS
EARNINGS (LOSS) (UNAUDITED):
Three months ended Nine months ended
September 30, September 30,
------------------------- --------------------------
2005 2004 2005 2004
---------- ---------- ---------- ----------
Discontinued operations revenues $ - $1,483,639 $ - $ 5,483,085
========== ========== ========== ===========
Discontinued operations earnings (loss)
before gain on sale of property
and equipment $ 17,462 $ 271,101 $ (275,492) $ 947,041
Gain on sale of property and equipment from
discontinued operations *
2,050 138,055 69,402 138,055
---------- ---------- ---------- -----------
Earnings (loss) from discontinued operations $ 19,512 $ 409,156 $ (206,090) $1,085,096
========== ========== ========== =+=========
* The assets sold for the three and nine months ended September 30, 2005, were
fully depreciated at the time of sale.
I-8
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
RESULTS OF OPERATIONS
In July 2004, management determined that the Company would wind down and
cease its contract manufacturing operations by December 31, 2004. Because of
this, the past and future financial results related to contract manufacturing
have been treated as discontinued operations for financial reporting purposes.
Continuing operations consist of operations related to the surviving
intellectual property licensing and holding company. The Company accounts for
its discontinued operations under the provisions of SFAS No. 144, "Accounting
for the Impairment or Disposal of Long-Lived Assets ". Accordingly, results of
operations and the related charges for discontinued operations have been
classified as "Earnings (loss) from discontinued operations" in the accompanying
Condensed Statements of Operations. Assets and liabilities of the discontinued
operations have been reclassified and reflected in the accompanying Balance
Sheets as "Discontinued operations". For comparative purposes, all prior periods
presented have been restated to reflect the reclassifications on a consistent
basis.
COMPARISON OF THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2005 AND 2004
RESULTS OF CONTINUING OPERATIONS
The Company recorded royalty income of $68,717 and $189,195 during the
three and nine months ended September 30, 2005, respectively, related to its
licensing agreement with Novartis. The Company recorded licensing fee income
from continuing operations of $1,065,000 for the three and nine months ended
September 30, 2004, related to the Novartis Agreement, (See Note 5 of Notes to
Condensed Financial Statements on page I-7 of this Report).
For the third quarter ended September 30, 2005, the Company recorded a net
loss from continuing operations of $(19,133) , or $(0.00) per basic and diluted
share, compared to earnings from continuing operations of $747,683, or $0.19 and
$0.18 per basic and diluted share, respectively, for the same quarter in 2004.
For the nine months ended September 30, 2005, the Company recorded a net loss
from continuing operations of $(464,097), or $(0.11) per basic and diluted
share, respectively, compared to earnings from continuing operations of
$155,309, or $0.04 per basic and diluted share, for the same period in the 2004.
The decrease in net earnings from continuing operations for both the three and
nine month periods ended September 30, 2005 compared to the same periods in the
prior year were primarily due to the recognition of licensing fee income of
$1,065,000 during the third quarter ended September 30, 2004, and partially
offset by royalty income earned during 2005, in conjunction with general
operating expenses related to the current operations of the Company during 2005.
RESULTS OF DISCONTINUED OPERATIONS
The earnings from discontinued operations for the third quarter ended
September 30, 2005 was $19,512, or $0.00 per basic and diluted share, compared
to earnings from discontinued operations of $409,156 or $0.10 per basic and
diluted share for the same period in 2004. The earnings from discontinued
operations for the third quarter ended September 30, 2005 was due primarily to
the reversal of compensation expense for previous employees of the Company and
from miscellaneous sales of fully depreciated assets. For the nine months ended
September 30, 2005, the loss from discontinued operations was $(206,090), or
$(0.05) per basic and diluted share, compared to earnings from discontinued
operations of $1,085,096 or $0.27 and $0.26 per basic and diluted share,
respectively, for the same period in 2004. For the three and nine months ended
September 30, 2004, sales to the Company's largest customer, Novartis, were
$1,219,646 and $4,007,352, respectively. There were no product sales to any
customers during 2005. The decrease in the earnings from discontinued operations
for both the three and nine month periods in 2005 compared to the same periods
in 2004 is attributable to the completion of the wind down of contract
manufacturing operations.
NET RESULTS OF OPERATIONS
The net income for the third quarter ended September 30, 2005 was $379, or
$0.00 per basic and diluted share, compared to net earnings of $1,156,839, or
$0.29 and $0.28 per basic and diluted share, respectively, for the same period
in 2004. For the nine months ended September 30, 2005, the net loss was
$(670,187), or $(0.16) per basic and diluted share, compared to net earnings of
$1,240,405, or $0.31 and $0.30 per basic and diluted share, respectively, for
the same period in 2004. The overall decline in results of operations for the
three and nine month periods ended September 30, 2005 over the same periods in
the prior year is primarily due to the absence of net sales and gross profit
from discontinued operations related to the wind down of contract manufacturing
operations and the reasons stated above.
I-9
INCOME TAXES
The provision for income tax expense for the three and nine months ended
September 30, 2005 was offset principally by a valuation allowance for deferred
taxes. Federal and state income taxes for the three and nine months ended
September 30, 2004 of $14,582 resulted from alternative minimum taxes because of
a partial disallowance of available tax credits and net operating loss
carryforwards for those periods.
EFFECT OF INFLATION
Inflation has not had a significant impact on the Company's operations or
cash flow.
WIND DOWN OF MANUFACTURING OPERATIONS
In September 2003, the Company learned that, as a result of a change in
its internal supplier selection criteria, Novartis, the Company's largest
customer, intended to stop using the Company as a contract manufacturer for its
topical patches by the end of 2004. In addition, Johnson & Johnson Consumer
Products Company, the Company's second largest customer, also indicated that it
intended to stop using the Company as a contract manufacturer during 2004. Based
on this situation and without any other manufacturing prospects, in July 2004,
the Board of Directors determined that the Company would cease manufacturing
operations by December 31, 2004 and decided to become an intellectual property
licensing and holding company.
On July 19, 2004, the Company entered into the Novartis Agreement,
effective as of January 1, 2004. The Agreement replaced the Company's prior
licensing and supply agreement with Novartis dated May 8, 2002. The Agreement
required the Company to manufacture, sell and deliver to Novartis vapor patches
for sale to the pediatric market in the United States, Canada and Mexico. In
order to provide the Company with working capital funds necessary to enable it
to manufacture and deliver vapor patches to Novartis in accordance with the
Agreement, Novartis advanced up to $2,000,000 for use by the Company to pay
accounts payable and expenses incurred exclusively for the manufacture and
delivery of vapor patches. In consideration of any advanced funds, the Company
executed and delivered to Novartis a promissory note of $2,000,000 and a
security agreement. Under the security agreement, the Company pledged
substantially all of its assets. The note was repaid by the Company by the
delivery to Novartis of vapor patches under the Agreement. All amounts owed were
repaid as of December 31, 2004. Under the Agreement, Novartis had the option
until March 31, 2005 to extend the use of vapor patches to the adult cough/cold
category in the United States, Canada and Mexico at no additional cost and under
the same terms and conditions as set forth in the Agreement. On March 31, 2005,
Novartis notified the Company of its desire to exercise the option to enter the
adult market pursuant to the Agreement. There can be assurance that Novartis
will actually introduce any product into the adult market.
Under the Agreement, the Company granted Novartis an exclusive license
(the "License") to all of the intellectual property of the Company to the extent
that it is used or useful in the production of the vapor patches being supplied
under the Agreement for a fee of $1,065,000, which was paid to the Company by
Novartis as follows: (1) release of $250,000 in promissory note debt as of the
date of the Agreement, (2) payment of $407,500 in cash in July 2004, and (3)
payment of $407,500 in cash in September 2004. The License began on July 19,
2004, and will continue for the duration of any patents included in the licensed
intellectual property and, with respect to all other elements of the licensed
intellectual property, for the maximum duration permitted under applicable law
(maximum fourteen years). Upon the expiration of the patents included in the
licensed intellectual property, Novartis will have a non-revocable, perpetual,
fully paid-up license to the intellectual property used or useful in the
production of vapor patches for the pediatric market and the adult cough/cold
market. Commencing on January 1, 2005, Novartis is required by the Agreement to
pay royalties, at an agreed upon percentage, to the Company, based upon the net
sales of vapor patches by Novartis for each year the License is in effect.
In August 2004, Novartis purchased a cartoning machine from the Company
for a purchase price of $162,000. In December, 2004, the Company entered into a
capital equipment purchase agreement (the "Purchase Agreement") with Novartis.
Under the Purchase Agreement, Novartis paid the Company the contract price of
$733,100 in exchange for the Company's hydrogel coating and therapeutic
converting machinery and equipment. The contract price was
I-10
based upon Novartis taking delivery of the equipment at the Company's facility.
Upon closing of this disposition of assets to Novartis on December 29, 2004, the
Company's transformation from a manufacturing operation to an intellectual
property licensing and holding company was complete.
LIQUIDITY AND CAPITAL RESOURCES
Cash and cash equivalents decreased by $884,530 during the first nine
months of 2005 to $1,354,788 at September 30, 2005. The decrease in cash and
cash equivalents during the first nine months of 2005 was due to cash used in
operating activities of $665,408 consisting primarily of cash used for
continuing operations as well as severance and other manufacturing wind down
costs, the payment of a cash dividend of $246,824 during the first quarter of
2005, which was partially offset by the receipt of $119,584 in cash received
from royalties under the Novartis agreement. See the discussion under "Licensing
and Supply Agreement" in Note 5 of Notes to Condensed Financial Statements for a
description of the agreement with Novartis.
During the first nine months of 2005, the Company received $176,207 from
Novartis under accounts receivable related to discontinued operations and
received proceeds of $90,227 related to exercises of stock options. The Company
received proceeds of $69,402 from the sale of miscellaneous equipment and office
furniture having no book value during the first nine months of 2005. The Company
also expended and capitalized $60,000 in patent related costs. There are no
future material commitments for capital expenditures at September 30, 2005.
The Company had working capital of $1,274,709 and a current ratio of 6.67
at September 30, 2005 compared to working capital of $2,048,876 and a current
ratio of 4.93 at December 31, 2004. The decrease in working capital during the
first nine months of 2005 is primarily attributable to lower accounts payables
and accrued expenses as a result of the Company paying severance and
manufacturing wind down obligations, the payment of a cash dividend, and a
reduction in accounts receivable partially offset with an increase in royalty
receivable. The improvement in the Company's current ratio is a result of the
settlement of liabilities associated with the Company's discontinued operations
and the reasons stated above.
Shareholders' equity decreased to $1,524,390 at September 30, 2005 from
$2,282,082 at December 31, 2004, which is primarily due to the net loss for the
nine months ended September 30, 2005 coupled with the payment of a cash dividend
of $246,824 in March 2005, in conjunction with other items discussed above.
The Company believes its existing cash and cash equivalents will be
sufficient to fund continuing operations through 2005. However, cash and cash
equivalents may not be sufficient to fund continuing operations beyond 2005. The
Company's working capital requirements are dependent upon adequate levels of
royalty and licensing fee income to fund continuing operations. Royalty income
is uncertain because it is subject to factors that the Company cannot control.
Such factors include, but are not limited to, seasonality of the product
resulting from the severity of the flu/cough and cold conditions in the
marketplace, marketing efforts by Novartis, markets Novartis enters the product
into, and other factors which can cause fluctuations in the amount of royalty
income the Company receives. There can be no assurance because of these
uncertainties that future royalty income will be sufficient to fund continuing
operations. The royalty income of $189,195 recorded for the nine months ended
September 30, 2005 was based upon information provided by Novartis calculated as
a percentage of net sales of products covered under the licensing agreement the
Company has with Novartis. There can be no assurance that this result will be
indicative of results for the full year. Furthermore, future royalties and
licensing income the Company anticipates earning is dependent on the success of
the product in the marketplace by Novartis and other firms or individuals with
whom the Company may enter into licensing agreements. Additionally, the Company
does not presently have any other financing resources in place from which it can
borrow or obtain additional working capital.
CRITICAL ACCOUNTING POLICIES
Management believes that the Company has not adopted any critical
accounting policies which, if changed, would result in a material change in
financial estimates, financial condition, results of operation or cash flows for
the three and nine months ended September 30, 2005 and 2004. The critical
accounting policies appear in Note 2 of Notes to Condensed Financial Statement
in this Form 10-QSB.
I-11
ITEM 3 - CONTROLS AND PROCEDURES
Under the supervision and with the participation of our management,
including our principal executive and financial officer, we have evaluated the
effectiveness of the design and operation of our disclosure controls and
procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934 (the "Exchange Act")). Based upon this evaluation, the
principal executive and financial officer has concluded that, as of the end of
the period covered by this report, our disclosure controls and procedures were
effective.
During the three months ended September 30, 2005, there were no changes in
the Company's internal control over financial reporting (as defined in Rule
13a-15(f) under the Exchange Act) that has materially affected, or is reasonably
likely to materially affect, the Company's internal control over financial
reporting.
I-12
PART II - OTHER INFORMATION
ITEM 1 - LEGAL PROCEEDINGS
None.
ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3 - DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
ITEM 5 - OTHER INFORMATION
None.
ITEM 6 - EXHIBITS
Exhibit No. Description
- ----------- -----------------------------------------------------------------
3.01 Articles of Incorporation of LecTec Corporation, as amended
(Incorporated herein by reference to the Company's Form S-1
Registration Statement (file number 33-9774C) filed on October
31, 1986 and amended on December 12, 1986).
3.02 Bylaws of LecTec Corporation (Incorporated herein by reference to
the Company's Form S-1 Registration Statement (file number 33-9774C)
filed on October 31, 1986 and amended on December 12, 1986).
31.01 Certification of Chief Executive Officer Pursuant to Section 302
of the Sarbanes-Oxley Act of 2002, filed herewith.
31.02 Certification of Acting Chief Financial Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.
32.01 Chief Executive Officer and Acting Chief Financial Officer
Certification Pursuant to #18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed
herewith.
99.01 Cautionary Statements (Incorporated herein by reference to Exhibit
99.01 to the Company's Report on Form 10-KSB for the fiscal year
ended December 31, 2004).
II-1
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
LECTEC CORPORATION
Date November 14, 2005 By /s/ Alan C. Hymes, M.D.
---------------------------
Alan C. Hymes, M.D.
Chief Executive Officer & Director
(principal financial officer and duly
authorized officer)
II-2
EXHIBIT INDEX
Exhibit No. Description
- ---------- ----------------------------------------------------------------
3.01 Articles of Incorporation of LecTec Corporation, as amended
(Incorporated herein by reference to the Company's Form S-1
Registration Statement (file number 33-9774C) filed on
October 31, 1986 and amended on December 12, 1986).
3.02 Bylaws of LecTec Corporation (Incorporated herein by reference
to the Company's Form S-1 Registration Statement (file number
33-9774C) filed on October 31, 1986 and amended on December 12,
1986).
31.01 Certification of Chief Executive Officer Pursuant to Section
302 of the Sarbanes-Oxley Act of 2002, filed herewith.
31.02 Certification of Acting Chief Financial Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.
32.01 Chief Executive Officer and Acting Chief Financial Officer
Certification Pursuant to #18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed
herewith.
99.01 Cautionary Statements (Incorporated herein by reference to
Exhibit 99.01 to the Company's Report on Form 10-KSB for the
fiscal year ended December 31, 2004).